

**CONCLUSION:** This trial failed to demonstrate a benefit of antioxidant supplementation in reducing the rate of gestational hypertension, preeclampsia and adverse conditions among patients with or without risk factors.

0002-9378/\$ – see front matter • doi:10.1016/j.ajog.2009.10.017

### 3 Magnesium sulfate to prevent adverse neurological injury: providing biological evidence


Irina Burd<sup>1</sup>, Kelsey Breen<sup>1</sup>, Alexander Friedman<sup>1</sup>, Jinghua Chai<sup>1</sup>, Michal Elovitz<sup>1</sup>

<sup>1</sup>University of Pennsylvania, Maternal and Child Health Research Program; OBGYN; CRRWH, Philadelphia, Pennsylvania

**OBJECTIVE:** Recent clinical trials suggest that antenatal exposure to magnesium sulfate (MG) reduces the risk of adverse neurological outcomes in ex-preterm children. About 70% of preterm infants result from spontaneous preterm birth (PTB) which is highly associated with intrauterine inflammation. Using a mouse model of intrauterine inflammation, these studies sought to assess if MG prevents brain injury.

**STUDY DESIGN:** CD-1 mice on E15-16 were randomized to intrauterine infusion (IU) of LPS or saline (NS). After IU, dams were randomized to intraperitoneal (IP) treatment with MG (270mg/kg X1, then 27mg/kg q20 min for 4 hrs and 2nd dose of 270mg/kg) or equal volumes of NS. From the 4 treatment groups, (IU NS+IP NS; IU LPS+IP NS; IU LPS+IP MG; and IU NS+IP MG), fetal brains (FB) were collected and neuronal cultures were created. Immunocytochemistry and confocal microscopy were performed to assess morphology and number of dendritic processes. FB from the 4 groups were used to investigate mRNA expression of cytokines, cell death, and neuronal and glial differentiation.

**RESULTS:** IL1 mRNA was differentially expressed between the treatment groups ( $P=0.009$ ); LPS+NS and LPS+MG had increased IL1 levels compared to controls. Markers of pro-oligodendrocytes were altered by LPS+NS but not by LPS+MG ( $P=0.06$ ). Caspase-1 mRNA was increased 1.3-fold in LPS and 1.6-fold in LPS+MG compared to controls ( $P=0.03$ ). Neuronal cultures from LPS+NS demonstrated fragility, decreased aggregation, and a reduced number of dendritic processes; this neuronal injury was prevented by MG ( $*P<0.001$ , FIG).



**CONCLUSION:** Prevention of neuronal injury in inflammation-associated PTB may be a key mechanism by which MG prevents cerebral palsy. These studies provide biological plausibility for the clinical use of MG in preterm deliveries.

0002-9378/\$ – see front matter • doi:10.1016/j.ajog.2009.10.018

### 4 Induction of labour versus expectant monitoring for intrauterine growth restriction at term (The Digitat Trial): a multicentre randomised controlled trial

Kim Boers<sup>1</sup>, Sylvia Vijgen<sup>2</sup>, Denise Bijlenga<sup>2</sup>, Joris Van Der Post<sup>3</sup>, Dick Bekedam<sup>4</sup>, Anneke Kwee<sup>5</sup>, Paulien Van Der Salm<sup>6</sup>, Marielle Van Pampus<sup>7</sup>, Marc Spaanderma<sup>8</sup>, Karin De Boer<sup>9</sup>, Hans Duvekot<sup>10</sup>, Henk Bremer<sup>11</sup>, Tom Hasaart<sup>12</sup>, Friso Delemarre<sup>13</sup>, Kitty Bloemenkamp<sup>1</sup>, Claudia Van Meir<sup>14</sup>, Christine Willekes<sup>15</sup>, Ella Wijnen<sup>16</sup>, Monique Rijken<sup>17</sup>, Saskia Le Cessie<sup>18</sup>, Frans Roumen<sup>19</sup>, Jan Van Lith<sup>1</sup>, Ben Willem Mol<sup>3</sup>, Sicco Scherjon<sup>1</sup>

<sup>1</sup>Leiden University Medical Center, Obstetrics, Leiden, Netherlands, <sup>2</sup>Academic Medical Centre, Amsterdam, Netherlands, <sup>3</sup>Academic Medical Center, Obstetrics and Gynecology, Amsterdam, Netherlands, <sup>4</sup>Onze Lieve Vrouwe Gasthuis, Obstetrics, Amsterdam, Netherlands, <sup>5</sup>University Medical Center, Obstetrics, Groningen, Netherlands, <sup>6</sup>Meander Medical Center, Obstetrics, Amersfoort, Netherlands, <sup>7</sup>Academic Medical Center, Obstetrics, Groningen, Netherlands, <sup>8</sup>UMC St Radboud, Obstetrics, Nijmegen, Netherlands, <sup>9</sup>Hospital Rijnstate, Obstetrics, Arnhem, Netherlands, <sup>10</sup>Erasmus Medical Center, Obstetrics, Rotterdam, Netherlands, <sup>11</sup>Reinier de Graaf Hospital, Obstetrics, Delft, Netherlands, <sup>12</sup>Catharina ZH, Obstetrics & Gynaecology, Tilburg, Netherlands, <sup>13</sup>Elkerliek Hospital, Obstetrics & Gynaecology, Helmond, Netherlands, <sup>14</sup>Groene Hart Hospital, Obstetrics and gynaecology, Gouda, Netherlands, <sup>15</sup>Academic Medical Center, Obstetrics, Maastricht, Netherlands, <sup>16</sup>VieCuri, Obstetrics & gynaecology, Venlo, Netherlands, <sup>17</sup>Leiden University Medical Centre, neonatology, Leiden, Netherlands, <sup>18</sup>Leiden University, Medical Statistics, Leiden, Netherlands, <sup>19</sup>Atrium Medical Center, Obstetrics, Heerlen, Netherlands

**OBJECTIVE:** Induction of labour is common treatment for pregnant women with a fetus suspected of intrauterine growth restriction (IUGR) at and near term, but its effectiveness has never been assessed in a randomised controlled trial.

**STUDY DESIGN:** We conducted a multicentre randomised controlled trial in 52 hospitals in the Netherlands, between November 2004 and November 2008. Pregnant women with a singleton pregnancy suspected of IUGR beyond 36+0 weeks of gestation were randomly allocated to either induction of labour or expectant monitoring using a web-based allocation system. The primary outcome was a composite measure of adverse neonatal outcome, defined as death before hospital discharge, a 5-minute Apgar score <7, an umbilical artery pH <7.05 or admission to the neonatal intensive care. Secondary outcome was operative delivery. Analysis was by intention-to-treat. This trial has been assigned the ISRCTN 10363217.

**RESULTS:** We randomly allocated 321 women to induction of labour and 329 women to expectant monitoring. Time until delivery was 0.9 days (IQR 0.7-1.7) in the induction group vs 10.1 days (IQR 5.5 – 16.0) in the expectant monitoring group (difference of the mean - 9.6 days [95% CI - 10.9; - 8.4],  $p<0.001$ ). Median birth weight was significantly lower in the induction group; 2410 grams ([IQR 2212 - 2655] vs 2580 grams ([IQR 2267 - 2870]; mean difference - 147 grams [95% CI - 208; - 87],  $p<0.001$ ). Composite adverse neonatal outcome occurred in 16 cases in the induction group versus 16 cases in the expectant monitoring group (6.2% vs 6.1%; difference 0.1% [95% CI - 4.0%; 4.1%],  $p=1.0$ ). The number of caesarean sections was also comparable in both groups ( $n=41$  versus  $n=41$ ; 13.6% vs 13.3%; difference 0.3% [95% CI - 5.2%; 5.7%],  $p=0.9$ ).

**CONCLUSION:** In women with a singleton fetus suspected of growth retardation at term, a strategy of induction of labour is equally effective as a strategy of expectant monitoring.

0002-9378/\$ – see front matter • doi:10.1016/j.ajog.2009.10.019